# Elegen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elegen

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.elegenbio.com
- Total disclosed funding: $35M
- Latest round: Series B (May 14, 2024)
- Investors on record: 10

## About

Established in 2017 by Matthew Hilland based in California, US, Elegen Corp. is an organization engaged in the study and advancement of DNA synthesis solutions.In May 2024, Elegen Corp. raised USD 35 million in Series B funding led by Triatomic Capital, with participation from GSK Venture Fund. Andreessen Horowitz, KdT Ventures, 8VC, Digitalis Ventures, ACVC Partners, Alix Ventures, AME Cloud Ventures, and Agilent Technologies.

Elegen Corporation's core product offering is ENFINIA DNA, a high-accuracy, cell-free DNA synthesis technology designed to produce long, complex, linear DNA sequences that enable clients to access synthetic DNA, reducing the traditional timeframes required for DNA synthesis and assembly. Customers include genetic medicine developers, researchers in synthetic biology, and organizations engaged in gene therapy, particularly those focused on mRNA vaccine development and advanced genetic research. ENFINIA DNA is utilized globally, with demand in North America, Europe, and Asia. This technology allows users to streamline their workflows by minimizing or eliminating the need for cloning practices, thus expediting critical research timelines.

The company generates revenue through direct sales of its ENFINIA DNA synthesis services, which are primarily targeted at B2B clients within the biotechnology and pharmaceutical sectors. 

The company intends to use the May 2024 funding to develop both its ENFINIA and its genetic medications.

## Funding rounds

- Series B, May 14, 2024, $35M — Agilent Technologies, Andreessen Horowitz, AME Cloud Ventures, 8VC, Digitalis Ventures, KdT Ventures, GSK Venture Fund, Alix Ventures, ACVC Partners, Triatomic Capital

## Investors

- Agilent Technologies — Series B
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series B
- AME Cloud Ventures (https://capitalatlas.ai/funds/ame-cloud-ventures) — Series B
- 8VC (https://capitalatlas.ai/funds/8vc) — Series B
- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Series B
- KdT Ventures (https://capitalatlas.ai/funds/kdt-ventures) — Series B
- GSK Venture Fund — Series B
- Alix Ventures (https://capitalatlas.ai/funds/alix-ventures) — Series B
- ACVC Partners (https://capitalatlas.ai/funds/acvc-partners) — Series B
- Triatomic Capital (https://capitalatlas.ai/funds/triatomic-capital) — Series B